Key points
- NAD+ is central to brain energy metabolism, which gives "NAD+ as a nootropic" a plausible mechanism — but plausibility isn't proof.
- When human trials measured cognition directly, NAD+ precursors reliably raised NAD+ levels yet mostly failed to beat placebo on cognitive outcomes.
- If you're chasing focus or clearing brain fog, NAD+ is a reasonable but unproven lever; sleep, exercise, and treating underlying causes have far stronger evidence.
Short answer: NAD+ has a genuine mechanistic case as a brain supplement, but it doesn't yet have the human evidence to be called a proven nootropic. Trials that gave people NAD+ precursors and then measured cognition directly have repeatedly shown the same pattern: NAD+ levels go up, but scores on cognitive tests don't reliably beat placebo. So the fair reading is that NAD+ is a biologically reasonable, still-unproven option for focus and mental clarity — not a sharpening agent you should expect to feel.
Why would NAD+ work as a nootropic at all?
The brain is metabolically expensive. NAD+ is the coenzyme that lets mitochondria turn fuel into ATP, and it also powers sirtuins and DNA-repair enzymes involved in cellular maintenance. NAD+ levels decline with age, and lower NAD+ has been associated with reduced cerebral blood flow and impaired energy metabolism in some models. The nootropic hypothesis follows logically: restore NAD+, restore the cellular conditions for sharp thinking. Rodent studies of neurodegeneration have shown brain-function improvements with the NAD+ precursor nicotinamide riboside (NR), which is what fueled human interest in the first place.
That's a real mechanism — but mechanisms generate hypotheses, not conclusions. Plenty of compounds that should work on paper don't survive contact with a placebo-controlled trial. To see how this plays out for energy specifically, our piece on whether NAD+ actually makes you feel less tired tells a similar story.
What human studies actually show
In long-COVID, NR raised NAD+ but did not significantly improve cognition. A 24-week double-blind, placebo-controlled trial gave 58 people with long-COVID up to 2,000 mg/day of NR. NAD+ levels rose 2.6- to 3.1-fold within 5–10 weeks — the supplement clearly "worked" biochemically — yet there was no significant improvement in cognition, fatigue, sleep, or mood versus placebo on the primary outcomes (PMID 41357333; DOI 10.1016/j.eclinm.2025.103633). The trial was funded by an NR manufacturer, which makes the null cognitive result all the more notable.
In mild cognitive impairment, early trials were designed for safety, not proof of benefit. A randomized placebo-controlled pilot gave older adults with mild cognitive impairment (MCI) about 1 g/day of NR for 10 weeks, with the Montreal Cognitive Assessment (MoCA) as a primary cognitive measure and cerebral blood flow as a secondary outcome (Orr et al.). A separate 12-week phase-II pilot randomized 52 older adults with amnestic MCI to NR 500 mg twice daily, reporting no serious adverse effects and comparable tolerability to placebo (PMC12724761). These were feasibility and safety studies — useful groundwork, but not powered to establish that NR sharpens cognition.
The honest counterweight. The strongest cognition-focused human data we have shows NAD+ going up without cognition following. That doesn't mean NAD+ is useless for the brain — the trials were in specific clinical populations, some were small, and exploratory within-group signals hint that longer or larger studies are worth running. But anyone selling NAD+ as a guaranteed focus booster is ahead of the evidence.
Study snapshot — the long-COVID cognition trial
Design: 24-week double-blind RCT, placebo lead-in. Population: 58 adults with long-COVID. Dose: NR up to 2,000 mg/day. Result: NAD+ rose 2.6–3.1× within 5–10 weeks, but no significant benefit over placebo on cognition, fatigue, sleep, or mood. Industry-funded.
Illustrative schematic, not plotted from trial data: NAD+ precursors reliably raise NAD+ levels, while the cognitive benefit measured against placebo has been flat in the trials to date.
What NAD+ won't do for your brain
NAD+ is not a stimulant. It won't produce the acute, felt "focus" of caffeine or prescription cognitive enhancers, and the trial evidence doesn't support expecting a measurable bump in test performance. If your "brain fog" stems from poor sleep, an underactive thyroid, depression, anemia, a medication side effect, or another medical cause, an NAD+ supplement won't fix the root issue — and it could delay finding it. If brain fog is persistent, worsening, or interfering with daily life, see a clinician. Cognitive symptoms are exactly the kind of thing that deserves a real evaluation rather than a supplement guess.
If you still want to try it: dose and timeline
The human trials above used NR in the range of roughly 500–2,000 mg/day, most commonly around 1 g/day, taken for weeks to months. If you experiment, give it a realistic window — the trials ran 10–24 weeks, so a two-week trial tells you little beyond tolerability. Pair it with the levers that genuinely move cognition: consistent sleep, regular exercise, and managing stress. Think of NAD+ as a maintenance-of-cellular-energy bet, not an acute nootropic, and judge it accordingly. For the precursor landscape, our comparison of NR vs. NMN vs. NAD+ explains which forms have the most human data.
Frequently asked questions
Is NAD+ a nootropic?
Mechanistically it's a candidate, but it isn't a proven one. The human trials that measured cognition directly mostly showed no significant benefit over placebo, even when NAD+ levels rose. Call it plausible-but-unproven.
Will NAD+ help with brain fog?
There's no strong trial evidence that it reliably clears brain fog. Because brain fog often has a treatable underlying cause, the higher-yield move is identifying that cause with a clinician rather than reaching for NAD+ first.
NAD+ vs. NMN vs. NR for the brain — which is best?
Most cognition trials used NR, so it has the most direct human data, but none of the precursors has clearly outperformed placebo on cognitive outcomes. There's no evidence-based "best one for the brain" yet.
How long until I'd notice anything?
The trials ran 10–24 weeks. If anything, benefits in this space accumulate slowly, so a few days won't tell you much. Tolerability shows up fast; cognitive effects, if real, would not.
Can I stack NAD+ with other nootropics?
People do, but stacking multiplies unknowns and makes it impossible to tell what's doing what. If you have a medical condition or take medication, talk to a clinician before combining supplements.
From Nuvirox
Why we formulated NAD+ Restore
NAD+ Restore is built around 500 mg of Nicotinamide Riboside Chloride (NR) per 2-capsule serving — one of the two most-researched NAD+ precursors, within the dose range used in published human trials. We add 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support — plus 10 mg galactomannans from fenugreek to support absorption. Backed by a 60-day money-back guarantee, long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
NAD+ earns its place in the nootropic conversation on mechanism — it's the coenzyme behind brain energy metabolism, and it declines with age. But the human trials that actually measured thinking tell a humbler story: NAD+ levels rise, and cognition mostly doesn't follow, at least not enough to beat placebo. That makes NAD+ a reasonable, unproven experiment rather than a reliable cognitive enhancer. If focus and mental clarity are the goal, put your effort first into sleep, exercise, and ruling out treatable causes — and treat NAD+ as a long-game cellular-maintenance bet, not a switch you flip for sharper afternoons.
References
- Wu CY, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine. 2025. PMID: 41357333. DOI: 10.1016/j.eclinm.2025.103633.
- Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024.
- A phase-II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. PMC12724761.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.